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Mean score differences (MSD) and 95% confidence inter-
vals (CI) were analyzed using ANCOVA and adjusted for 
age, sex, tumor stage, comorbidity, education level, hospital 
volume, and postoperative complications. MSDs > 10 were 
regarded as clinically relevant.
Results Among 176 patients with complete information 
on HRQOL and covariates, none of the MSDs for HRQOL 
among the three surgery groups were clinically and statisti-
cally significant. MSDs comparing esophagectomy and gas-
trectomy showed no major differences in global quality of 
life (MSD, +8, 95% CI, 0 to +16), physical function (MSD, 
+2, 95% CI, −5 to +9), pain (MSD, −3, 95% CI, −12 to +7), 
or reflux (MSD, +5, 95% CI, −4 to +14). Also, complica-
tion rates and 5-year survival rates were similar comparing 
esophagectomy and gastrectomy.
Conclusions Extended total gastrectomy, subtotal 
esophagectomy, and combined esophagogastrectomy 
seemed to yield similar 6-month postoperative HRQOL 
outcomes for patients with GEJ adenocarcinoma.
Keywords Esophageal neoplasm · Gastric cancer · 
Surgery · Symptoms · Functions
Introduction
The curative treatment of adenocarcinoma of the gastroe-
sophageal junction (GEJ) typically includes surgical resec-
tion. Multimodal treatment and centralization of surgery 
have improved the 5-year survival rate [1, 2], but there is an 
ongoing debate about the optimal surgical approach for GEJ 
cancer [3]. None of the different surgical alternatives, i.e., 
total gastrectomy, subtotal esophagectomy, or a combina-
tion of these approaches, i.e., esophagogastrectomy, seems 
to offer superior oncological outcomes [4, 5]. However, it 
Abstract 
Background The postoperative health-related qual-
ity of life (HRQOL) outcomes in patients with gastroe-
sophageal junction (GEJ) adenocarcinoma after gas-
trectomy and esophagectomy are unclear. The aim was 
to evaluate HRQOL outcomes 6 months after extended 
total gastrectomy, subtotal esophagectomy, and combined 
esophagogastrectomy.
Methods Patients who underwent surgery for GEJ adeno-
carcinoma of Siewert type 2 or 3 in 2001–2005 were identi-
fied from a nationwide Swedish prospective and population-
based cohort. Three surgical strategies, i.e., gastrectomy, 
esophagectomy, or esophagogastrectomy, were analyzed in 
relationship to HRQOL measured at 6 months after surgery 
(main outcome). HRQOL was assessed using well-validated 
questionnaires for general (EORTC QLQ-C30) and esopha-
geal cancer-specific (EORTC QLQ-OES18) symptoms. 
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is important to also consider patients’ postoperative health-
related quality of life (HRQOL). Poor HRQOL at 6 months 
after surgery for esophageal or gastroesophageal junction 
cancer is associated with increased long-term mortality [6, 
7], as is poor HRQOL up to 10 years postoperatively [8–10]. 
HRQOL outcomes of extended total gastrectomy and sub-
total esophagectomy have been studied only in a few, small, 
single-center studies with inherent problems with statistical 
power and selection bias. There is a need for larger studies 
based on unselected patients comparing extended gastrec-
tomy, subtotal esophagectomy, and combined esophago-
gastrectomy, specifically examining patients with Siewert 
II and III GEJ cancer. Therefore, the aim of this study was 
to elucidate whether any of the three main alternative surgi-
cal procedures for GEJ cancer of Siewert II and III has a 
different impact on postoperative HRQOL at 6 months in 
a population-based and nationwide Swedish cohort study.
Patients and methods
Study design and data sources
We report here a nationwide Swedish, population-based, 
and prospective cohort study derived from the Swedish 
Esophageal and Cardia Cancer cohort (SECC), which has 
been described in detail elsewhere [10]. In brief, the SECC 
includes 90% of all patients who underwent surgery with 
curative intent for esophageal or GEJ cancer in Sweden 
during the period April 2, 2001 to December 31, 2005; 
these patients were followed up until February 2016. The 
prospectively collected information for the SECC included 
data on patient and tumor characteristics, surgical details, 
pre-defined complications occurring within 30 days of sur-
gery, and the self-reported written HRQOL questionnaire 
at 6 months after surgery. Additionally, we obtained socio-
economic data from the Longitudinal Integration Database 
for Health Insurance and the Labor Market Studies (LISA) 
database, and information on comorbidities was obtained 
from the Swedish Patient Registry. The Registry of the Total 
Population provided highly accurate mortality data. All par-
ticipating patients gave informed consent. The study was 
approved by the Regional Ethical Review Board in Stock-
holm, Sweden.
Patients
Among all 616 patients enrolled in the SECC, 282 patients 
with a Siewert type II or III GEJ adenocarcinoma were eli-
gible for the present study. Tumors of included patients had 
an epicenter up to 1 cm above or up to 5 cm below the GEJ 
[11]. Tumor staging was done according to the 6th edition of 
TNM classification of malignant tumors [12]. Location and 
tumor stage information was obtained from the pathology 
reports of the resected specimen.
Exposure
Study exposure was any of the following three surgical 
procedures.
(1) Total gastrectomy with resection of the distal esopha-
gus through laparotomy and anastomosis just above the 
diaphragm; these patients were labeled the “gastrec-
tomy group.”
(2) Subtotal esophagectomy with resection of the proximal 
stomach through abdominal and thoracic incisions, and 
sometimes also neck incision, with a gastric pull-up 
reconstruction and an anastomosis in the upper chest or 
neck; these patients were labeled the “esophagectomy 
group.”
(3) Combination of groups (1) and (2) with esophago-
gastrectomy and a long jejunal Roux-en-Y or colonic 
interposition with intrathoracic or neck anastomosis; 
these patients were labeled the “esophagogastrectomy 
group.”
Outcomes
The primary outcome was HRQOL at 6 months after sur-
gery. HRQOL was measured using well-established ques-
tionnaires developed and validated by the European Organ-
isation for Research and Treatment of Cancer (EORTC) 
[13, 14]. The 30-item core questionnaire (QLQ-C30) has 9 
multi-item scales measuring global quality of life, functions 
(physical, role, cognitive, emotional and social functioning) 
and symptoms (fatigue, pain, nausea and vomiting), and 6 
single items measuring symptoms common among cancer 
patients in general (dyspnea, appetite loss, insomnia, con-
stipation, diarrhea, financial impact) [13]. Symptoms com-
mon among esophageal cancer patients were measured with 
the supplemental module QLQ-OES18, which comprises 4 
symptom scales (eating, reflux, esophageal pain, dyspha-
gia) and 6 single items (cough, dry mouth, taste, choking, 
speech, and trouble swallowing saliva) [14]. Each item (on 
both questionnaires) has four response categories: “not at 
all,” “a little,” “quite a bit,” and “very much,” except for the 
global quality of life scale, which has seven response alter-
natives ranging from “very poor” to “excellent.”
Secondary outcomes were pre-defined complications 
within 30  days of surgery, as defined earlier [15], and 
5-year overall mortality. The following complications were 
included: postoperative bleeding (>2 l or requiring reop-
eration), anastomotic leakage (symptomatic and verified 
clinically or radiologically), intraabdominal or intratho-
racic abscesses (symptomatic or verified radiologically), 
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sepsis (symptomatic with positive blood culture), pneumo-
nia (symptomatic and verified radiologically), renal failure 
(need of dialysis), pulmonary embolism (verified radiologi-
cally), myocardial infarction (verified by electrocardiogram 
and enzymes), stroke (verified radiologically), and respira-
tory failure (need of intubation or mechanical ventilation).
Statistical analysis
The HRQOL questionnaire responses were transformed 
into scores between 0 and 100, and missing items were 
handled as recommended in the EORTC scoring man-
ual [16]. Higher scores correspond to better HRQOL in 
the function scales and the global quality of life scale, 
whereas higher scores in symptom scales and items rep-
resent more problems. The main analysis included all the 
patients selected according to Fig. 1. Subgroup analysis 
for the primary and secondary outcomes was restricted 
to patients with Siewert type II GEJ cancer. Adjusted 
mean HRQOL scores for each surgical procedure were 
calculated with 95% confidence intervals (CI). Analysis 
of covariance (ANCOVA) was used to calculate adjusted 
mean score differences (MSD) with 95% CIs among the 
three surgery groups. Adjustment for confounding factors 
utilized a priori selected covariates potentially affecting 
HRQOL: age (categorized into <60 years, 60–74 years, or 
>74 years), sex (male or female), comorbidity (no or yes), 
tumor stage (0–I, II, III, or IV), education (9-year com-
pulsory education, upper secondary education, or higher 
education), hospital volume (0–3, 4–9, or ≥10 operations 
per year), and pre-defined complications within 30 days 
of surgery (no or yes). To reduce errors resulting from 
multiple testing, we tested for statistical significance only 
when the MSDs were at least 10 between groups using the 
Fig. 1  Flowchart of the study 
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chi-square test. Such differences are considered clinically 
relevant and noticeable for the patient according to previ-
ous studies [17, 18].
To evaluate the association between surgical proce-
dures and risk of pre-defined major complications, we 
used the multivariable logistic regression adjusted for the 
potential confounding variables already listed (except for 
complications). The relative risks were estimated using 
odds ratios (ORs) and 95% CIs.
Survival analysis used the Cox proportional hazards 
model while adjusting for the confounding variables listed 
here. The relative risks were expressed as hazard ratios 
(HRs) with 95% CIs.
The reference category in all statistical analyses was 
the gastrectomy group. The statistical software SAS V.9.4 




Among 282 patients with GEJ adenocarcinoma in the cohort, 
85 underwent gastrectomy, 155 underwent esophagectomy, 
and 42 had esophagogastrectomy. Among them, 229 patients 
(81%) survived for at least 6 months and 68 (24%) survived 
for 5 years or longer. Some characteristics of these 282 
included patients are summarized in Table 1: 181 (64%) 
patients had Siewert type II cancer, 86 (31%) had Siewert 
type III cancer, and 15 (5%) had undetermined Siewert type 
II or III cancer. The patients in the gastrectomy group were 
more likely to have Siewert type III cancer and undergo sur-
gery in a low-volume hospital compared to the esophagec-
tomy group. Patients undergoing esophagogastrectomy were 
younger, had less comorbidity, fewer early-stage tumors, and 
were more likely to be treated in a high-volume hospital. Of 
Table 1  Characteristics of the 
282 patients who underwent 
surgery for gastroesophageal 
junction adenocarcinoma of 
Siewert type II or III
Gastrectomy Esophagectomy Esophagogastrectomy Total
Number (%) Number (%) Number (%) Number (%)
Total 85 (100) 155 (100) 42 (100) 282 (100)
Age (in years)
 <60 19 (22) 38 (25) 15 (36) 72 (26)
 60–74 36 (42) 78 (50) 20 (48) 134 (48)
 >74 30 (35) 39 (25) 7 (17) 76 (27)
Sex
 Male 69 (81) 128 (83) 33 (79) 230 (82)
 Female 16 (19) 27 (17) 9 (21) 52 (18)
Education level
 9-year compulsory 47 (55) 72 (46) 13 (31) 132 (47)
 Upper-secondary 27 (32) 53 (34) 21 (50) 101 (36)
 Higher education 11 (13) 23 (15) 6 (14) 40 (14)
 Missing 0 (0) 7 (5) 2 (5) 9 (3)
Comorbidity
 Yes 51 (60) 97 (63) 20 (48) 168 (60)
 No 34 (40) 58 (37) 22 (52) 114 (40)
Siewert type
 II 37 (44) 122 (79) 22 (52) 181 (64)
 III 47 (55) 20 (23) 19 (45) 86 (31)
 Unclear II–III 1 (1) 13 (8) 1 (2) 15 (5)
Tumor stage
 0–I 19 (22) 29 (19) 2 (5) 50 (18)
 II 27 (32) 38 (25) 15 (36) 80 (28)
 III 25 (29) 66 (43) 18 (43) 109 (39)
 IV 14 (16) 17 (11) 5 (12) 36 (13)
 Missing 0 (0) 5 (3) 2 (5) 7 (2)
Hospital volume
 Low (0–3/year) 32 (38) 38 (25) 5 (12) 75 (27)
 Mid (4–9/year) 30 (35) 38 (25) 12 (29) 80 (28)
 High (≥10/year) 23 (27) 79 (51) 25 (60) 127 (45)
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the 229 patients surviving for 6 months, those 176 (77%) 
who responded to the HRQOL questionnaires and had com-
plete data on all covariates were included in the HRQOL 
analyses. The distribution of nonparticipating patients was 
similar among the three surgery groups (21% for gastrec-
tomy, 15% for esophagectomy, 17% for esophagogastrec-
tomy). Characteristics of these patients, their tumors, and 
treatment were similar to that of all 282 participants (see 
Supplementary Table 1). A flowchart describing the study 
participants throughout the study is shown in Fig. 1. Only 8 
patients (5%) received neoadjuvant therapy, and 11 patients 
(6%) received adjuvant therapy.
Health‑related quality of life 6 months after surgery
The adjusted HRQOL mean scores from the general cancer 
questionnaire (QLQ-C30) are presented in Table 2. Mean 
global quality of life scores were similar (MSD, +8, 95% CI, 
0 to +16), as were physical function (MSD, +2, 95% CI, −5 
to +9), and pain (MSD, −3 95% CI, −12 to +7) between the 
esophagectomy group and the gastrectomy group. Borderline 
MSDs were found for role function (MSD, +9, 95% CI, −3 
to +20 and cognitive function (MSD, +10 [rounded up], 
95% CI, +3 to +17) in the esophagectomy group compared 
to the gastrectomy group. Regarding general cancer symp-
toms, no clinically relevant differences were found between 
patients undergoing esophagectomy and the gastrectomy 
group (Table 2). However, patients in the esophagogastrec-
tomy group reported clinically significantly more dyspnea 
than did the gastrectomy group, although this difference was 
not statistically significant (MSD, +12, 95% CI, −3 to +26).
The adjusted esophageal-specific HRQOL scores (QLQ-
OES18) are presented in Table 3. No clinically relevant dif-
ferences were found among any of the three surgery groups; 
patients who underwent esophagectomy reported fewer 
problems with dry mouth, but this difference was not sta-
tistically significant (MSD, −10, 95% CI, −20 to 0). Scores 
for dysphagia (MSD, −5, 95% CI, −14 to +4), esophageal 
pain (MSD, −2, 95% CI, −10 to +6), and reflux symptoms 
(MSD, 5, 95% CI, −4 to +14) were similar after esophagec-
tomy compared to gastrectomy. A borderline clinical dif-
ference was found for coughing, wherein patients in the 
esophagectomy group reported higher scores than the gas-
trectomy group (MSD, +9, 95% CI, 0 to +18).
Table 2  Health-related quality of life outcomes from the European Organization of Research and Treatment of Cancer (EORTC) QLQ-C30 
questionnaire measures at 6 months after surgery for gastroesophageal junction adenocarcinoma of Siewert type II or III
Data are presented as adjusted mean scores and 95% confidence intervals (CI) and mean score differences. Clinically significant differences 
(mean score difference of >10 scores) between comparison groups are bolded
a Rounded value, not clinically significant
















 Global quality of life 54 (47–62) 63 (57–69) 59 (49–69) 8 5
Functions
 Physical 75 (68–81) 77 (72–82) 72 (63–80) 2 3
 Role 58 (47–68) 66 (58–75) 56 (42–70) 9 2
 Emotional 69 (62–76) 73 (68–79) 71 (61–80) 4 2
 Cognitive 75 (68–82) 85 (79–90) 84 (75–93) 10a 9
 Social 69 (60–78) 72 (65–79) 61 (49–73) 3 −8
Symptoms
 Fatigue 49 (41–57) 41 (34–47) 50 (39–61) −8 1
 Nausea/vomiting 25 (18–33) 24 (18–30) 16 (6–25) −1 −10a
 Pain 27 (18–36) 24 (17–31) 21 (9–33) −3 −6
 Dyspnea 25 (15–35) 30 (22–38) 37 (24–50) 5 12*
 Insomnia 26 (17–36) 25 (17–32) 20 (8–32) −2 −6
 Appetite loss 41 (29–52) 39 (30–48) 46 (31–61) −2 5
 Constipation 10 (3–17) 14 (9–20) 10 (1–19) 4 0
 Diarrhea 31 (21–41) 27 (19–36) 22 (8–35) −4 −9
 Financial problems 13 (6–21) 14 (8–20) 11 (1–21) 1 −2
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Subgroup analysis including only the 112 Siewert type 
II GEJ cancers suggested clinically relevantly better global 
quality of life (MSD, +17, 95% CI, +6 to +28), role (MSD, 
+11, 95% CI, −4 to +26), cognitive (MSD, +18, 95% CI, 
+8 to +28) and social function (MSD, +11, 95% CI, −2 to 
+25), as well as less fatigue (MSD, −14, 95% CI, −26 to 
−2) and less appetite loss (MSD, −11, 95% CI, −29 to +7) 
after esophagectomy compared to gastrectomy in the general 
cancer questionnaire (QLQ-C30) (Supplementary Table 2). 
The differences in global quality of life (p = 0.003), cogni-
tive function (p < 0.001), and fatigue (p = 0.023) were also 
statistically significant. In the esophageal cancer-specific 
QLQ-OES18 questionnaire, esophagectomy was associated 
with clinically relevantly less dry mouth (MSD, −12, 95% 
CI, −27 to +2) and taste symptoms (MSD, −10, 95% CI, 
−26 to +5), but neither of these differences was statistically 
significant (Supplementary Table 2).
Complications
In total, 97 (34%) of all 282 patients had at least one of the 
pre-defined complications within 30 days of surgery. Esoph-
agogastrectomy had the lowest absolute 30-day complication 
rates (14%); the rate was higher for gastrectomy (40%) and 
for esophagectomy (37%). After adjustment for confounding 
variables, no difference in risk of complications was found 
between esophagectomy and gastrectomy (OR, 0.90, 95% 
CI, 0.50–1.63), but the esophagogastrectomy group had sig-
nificantly lower complication rates compared to gastrectomy 
(OR, 0.31, 95% CI, 0.11–0.87).
In the subgroup analysis of patients with Siewert type II 
GEJ cancer, there was an indication of fewer complications 
following esophagectomy compared to gastrectomy, but no 
statistically significant association was found (HR, 0.43, 
95% CI, 0.18–1.03) (Supplementary Table 3).
Mortality
The absolute 5-year survival among all 282 patients was 
similar in the three surgery groups (24% for gastrectomy, 
25% for esophagectomy, and 24% for esophagogastrectomy). 
There were no statistically significant differences in 5-year 
overall survival rates after adjustment for confounding 
variables: HR, 0.85, 95% CI, 0.62–1.17 for esophagectomy 
versus gastrectomy and HR, 0.87, 95% CI, 0.54 to 1.39 for 
esophagogastrectomy versus gastrectomy.
In the subgroup analysis restricted to patients with Siew-
ert type II GEJ cancer, esophagectomy was associated with 
better survival compared to gastrectomy (HR, 0.62, 95% CI, 
0.39–0.96) (Supplementary Table 3).
Discussion
This study indicates that the choice between gastrectomy, 
esophagectomy, or esophagogastrectomy has no major 
influence on the HRQOL for GEJ cancer patients 6 months 
after surgery. The risks of complications and mortality 
were not clearly different when comparing the gastrectomy, 
esophagectomy, and esophagogastrectomy groups.
Table 3  Health-related quality of life outcomes from the European Organization of Research and Treatment of Cancer (EORTC) QLQ-OES18 
questionnaire measures at 6 months after surgery for gastroesophageal junction adenocarcinoma of Siewert type II or III
Data are presented as adjusted mean scores and 95% confidence intervals (CI) and mean score differences. Clinically significant differences 
[mean score difference (MSD) >10 scores] between comparison groups are in bold font
















 Dysphagia 30 (21–38) 25 (18–32) 30 (19–41) −5 0
 Eating difficulties 35 (27–43) 36 (29–42) 32 (21–42) 1 −3
 Reflux 20 (11–28) 25 (18–32) 11 (0–23) 5 −8
 Esophageal pain 27 (19–35) 25 (18–31) 22 (11–32) −2 −5
 Trouble swallowing saliva 17 (9–24) 18 (12–24) 11 (1–21) 2 −5
 Choked when swallowing 14 (6–22) 17 (11–23) 12 (2–22) 3 −2
 Dry mouth 33 (23–43) 23 (15–31) 35 (22–48) −10* 2
 Trouble taste 28 (18–38) 21 (13–29) 28 (15–41) −6 0
 Trouble coughing 16 (8–25) 26 (19–33) 23 (12–35) 9 7
 Trouble speaking 11 (4–17) 6 (0–11) 3 (−6 to 12) −5 −8
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The strengths and the limitations of the study should be 
considered when interpreting the results. The prospective, 
nationwide population-based design counteracts information 
bias, selection bias, and recall bias. The nonparticipating 
patients might have poorer HRQOL compared to the patients 
participating in the study. However, the distribution of non-
participating patients was similar among the surgery groups, 
and the compliance of the included patients was high (78%), 
making bias from this source less likely. The sample size 
was larger than in any other previous study on the topic. 
Neoadjuvant and adjuvant therapies became the standard of 
care only after the study period, which could be seen as a 
limitation. However, the low use of neoadjuvant and adju-
vant treatment in the study population prevented confound-
ing from these treatments. The well-validated EORTC ques-
tionnaires allow an accurate assessment of HRQOL in GEJ 
cancer patients [13, 14]. Finally, the results were adjusted for 
several potential confounding factors. The lack of baseline 
HRQOL data is a limitation. Thus, we could not adjust for 
potential preoperative differences in the HRQOL in the com-
parison groups. However, the characteristics of the patients 
were similar at baseline for the gastrectomy and esophagec-
tomy groups. In addition, we included only Siewert II and 
III GEJ cancers, in which the choice of surgical procedure 
is dependent on the surgeon’s preference and experience 
rather than patient characteristics. In Siewert type II can-
cer, esophagectomy was more common, whereas gastrec-
tomy was more common in type III patients. However, both 
procedures were used for both cancer types, confirming the 
rationale for including Siewert type II and III in the current 
study population. A larger proportion of esophagectomies 
were conducted in high-volume hospitals compared to gas-
trectomies, but this factor was adjusted for in the analyses. 
The small number of patients in the subgroup analyses, as 
well as patients who underwent esophagogastrectomy, limits 
the statistical power regarding these groups in particular. No 
p value correction was conducted, increasing the probability 
of false-positive findings (type I errors). Additionally, the 
patients who underwent esophagogastrectomy were younger 
and had less comorbidity at baseline. Therefore, the results 
of the subgroup analysis of Siewert type II, as well as those 
regarding the esophagogastrectomy group, must be inter-
preted with caution.
In previous studies, gastrectomy has been proposed to 
offer better short- and long-term postoperative HRQOL than 
esophagectomy, which is in conflict with the present study. 
However, the differences might be explained by methodolog-
ical issues, including bias from selection and confounding in 
earlier studies. A study from the United States of 27 patients 
indicated better HRQOL after gastrectomy compared to 
esophagectomy more than 3 months after surgery [19]. 
Similarly, a study of 63 patients from the United Kingdom 
suggested better HRQOL outcomes following gastrectomy 
compared to esophagectomy at 6 months after surgery [20]. 
However, both these investigations were small, single-center 
studies with apparent problems with selection bias [19, 20]. 
Also, a recent German hospital-based study including 123 
patients found a trend toward better HRQOL after gastrec-
tomy compared to esophagectomy at least 24 months after 
surgery, which was mainly the result of fewer respiratory and 
reflux-related symptoms [21]. However, only 127 (36%) of 
the 357 eligible patients participated, suggesting a high risk 
of selection bias, and no adjustment for confounding vari-
ables was made [21]. Moreover, if the suggested threshold 
for clinical significance of 10 points on the quality of life 
scale would have been used in that study [17, 18], the only 
measure that would have favored gastrectomy would have 
been dyspnea [21].
The results of the present investigation suggest that the 
three surgical alternatives under study are comparable 
regarding HRQOL outcomes at 6 months after surgery for 
GEJ cancer. We used 6 months as the time point for the 
assessment because this is a window after the initial post-
operative recovery period and before tumors tend to recur 
[7]. Poor HRQOL at 6 months has also been shown asso-
ciated with poor survival, as is poor HRQOL in the long 
term [6–10]. Physical function and pain, which should be 
the aspects most affected by the trauma caused by exten-
sive surgery, were only minimally different between the 
groups. It has been proposed previously that the perception 
of HRQOL after surgery is not affected to a large extent by 
major cancer surgery because the patients are happy about 
surviving [24]. It has been shown that HRQOL is affected 
more and continues to deteriorate postoperatively in patients 
with comorbidities, whereas the majority of patients recover 
well after surgery [25]. Surgical complications also predict 
poor HRQOL [15], stressing the relevance of adjusting for 
complications to examine the role of the surgical approach 
per se. According to a recent interview study, patients want 
more information on recovery and quality of life after sur-
gery [26]. Taken together, patients should be informed about 
the expected postoperative quality of life following surgery.
The subgroup analysis restricted to Siewert type II GEJ 
cancers only suggested that esophagectomy might be associ-
ated with better global HRQOL, cognitive function, as well 
as less fatigue, compared to gastrectomy, which is probably 
a result of the small number of patients in the analysis. A 
randomized controlled trial from Japan suggested aggra-
vated weight loss, symptoms such as reduced meal volume, 
more pain, and more dyspnea, as well as more respiratory 
problems, in the long term after surgery, including a thora-
cotomy (left thoracoabdominal approach) for gastric can-
cer, compared to a non-thoracotomy procedure (transhiatal 
abdominal approach) [22]. Greater surgical trauma might 
also associate with worse symptoms in a meta-analysis com-
paring HRQOL outcomes after minimally invasive and open 
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esophagectomy for cancer, at least in the short term [23]. 
However, the study populations and surgical approaches 
in these two studies are not entirely comparable with the 
present study. Taken together, the results of the subgroup 
analysis do not fit in the hypothesis that less surgical trauma 
results in better HRQOL, but do indicate a need for fur-
ther studies comparing HRQOL outcomes between surgical 
approaches in Siewert type II GEJ cancer.
The 30-day complication rates were similar between 
the gastrectomy (40%) and esophagectomy (37%) groups, 
whereas the lower complication rate in the esophago-
gastrectomy group is most likely explained by selection 
of more fit patients for such extensive surgery. As in this 
cohort, earlier comparative studies between gastrectomy and 
esophagectomy for GEJ cancer have reported complication 
rates between 30% and 54% [27–29]. There was no 5-year 
survival benefit for any of the operative techniques studied 
in the main analysis, which is well in line with most previ-
ous research [30–32], and stresses the relevance of study-
ing patient-reported outcomes. The observed association 
between esophagectomy and better 5-year survival in the 
subgroup analysis of Siewert type II GEJ cancer needs fur-
ther research in better powered studies.
In conclusion, the 6-month postoperative HRQOL seems 
to be similar comparing the surgical approaches of extended 
total gastrectomy, subtotal esophagectomy, and esophago-
gastrectomy in patients with GEJ adenocarcinoma of Siew-
ert type II and III. These results indicate that the choice of 
surgical approach could be based on the preference of the 
surgeon.
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